Precision Medicine

Akumin unveils its renovated Plantation facility, blending advanced United Imaging tech with patient-centered design to set a new standard for diagnostics.

TGA approves Minjuvi, a dual-targeted immunotherapy for relapsed follicular lymphoma, offering a breakthrough option beyond traditional chemotherapy.

A new financial deal shines a light on Modeyso, a breakthrough therapy for a rare pediatric brain cancer, linking Wall Street to life-saving innovation.

An essay contest for medical trainees aims to fix a critical gap in patient care, using frontline stories to reshape how doctors learn about nutrition.

With a fresh CAD $1M in funding, Grey Matters is set to enter the booming U.S. neuroimaging market, targeting early Alzheimer's detection.

With the hire of world-renowned surgeon Dr. Nelson Oyesiku, Piedmont Healthcare signals its ambition to become a top destination for neurological care in the Southeast.

A $500K grant accelerates a novel therapy that dismantles tumor defenses, offering new hope for patients with hard-to-treat gastroesophageal cancers.

With a seasoned dealmaker at the helm, Elkedonia is advancing a first-in-class, non-hallucinogenic drug for depression targeting a novel protein.

A record-breaking medical conference reveals a major shift in medicine, as practitioners move from simply managing aging to pursuing biological age reversal.

A novel drug that targets the cellular environment of the MYC cancer protein, not the protein itself, shows major promise in preclinical studies.

Hyalex Orthopaedics’ new FDA-cleared Slalom™ implant, using cartilage-mimicking tech, offers a motion-preserving alternative to joint fusion.

Obsidian Therapeutics will unveil pivotal Phase 2 data on OBX-115, an engineered cell therapy that may offer a safer, more potent weapon against melanoma.

A novel staple-like device from Inovedis gains expanded FDA approval, promising faster, less invasive repairs for a vast range of orthopedic injuries.

A new AI-driven platform moves beyond static reports, offering continuous genomic updates to give cancer patients access to the latest treatment options.

A new alliance between UltraGreen and LifeSignals will bring advanced wearable heart monitors to a global market, tackling rising cardiovascular disease.

A new partnership aims to develop a diagnostic test for a hidden cancer biomarker, potentially unlocking a targeted therapy for patients with grim prognoses.

A breakthrough study in a Nature journal reveals a novel device, RefluxStop, has a stellar long-term safety record, offering hope for millions with severe GERD.

Following a breakthrough in chondrosarcoma, Inhibrx Biosciences is set to reveal pivotal data for its drug ozekibart in the vast colorectal cancer market.

Freshly spun-off from AnaptysBio, First Tracks Biotherapeutics hits the market with a strong cash position and a pipeline aimed at celiac disease and RA.

Upcoming Phase 1 data for ABCL635 could validate a novel antibody approach for hot flashes, challenging the market and offering new hope for millions.